Zenas BioPharma (ZBIO) Net Cash Flow (2023 - 2026)
Zenas BioPharma (ZBIO) posted quarterly Net Cash Flow of $389.9 million for Q1 2026, up 416.41% year-over-year from $75.5 million in Q1 2025, and up 8000.59% quarter-over-quarter from -$4.9 million in Q4 2025.
Zenas BioPharma (ZBIO) Net Cash Flow (2023 - 2026) Analysis & Trends
Zenas BioPharma's Net Cash Flow history runs 4 years deep, the most recent figure standing at $389.9 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 416.41% year-over-year to $389.9 million; the TTM figure through Mar 2026 stood at $304.2 million (up 91.02% YoY), while the FY2025 annual figure was -$208.9 million, down 179.53% from the prior year.
- Net Cash Flow for Q1 2026 stood at $389.9 million, up from -$4.9 million in the prior quarter.
- The five-year high for Net Cash Flow was $389.9 million in Q1 2026, with the low at -$152.3 million in Q2 2025.
- The 4-year median for Net Cash Flow is -$10.1 million (2023), against an average of $42.8 million.
- The sharpest annual moves came in 2025 and 2026: Net Cash Flow tumbled 524.31% in 2025, then jumped 416.41% in 2026.
- Zenas BioPharma's Net Cash Flow stood at -$15.4 million in 2023, then tumbled by 163.43% to -$40.4 million in 2024, then jumped by 87.8% to -$4.9 million in 2025, then soared by 8000.59% to $389.9 million in 2026.
- Business Quant data shows ZBIO's Net Cash Flow at $389.9 million in Q1 2026, -$4.9 million in Q4 2025, and $71.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Zenas BioPharma | 1.87 Bn | 748.44 Mn | - | -302.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -302.88 Mn |
| Jun 30, 2026 | -302.88 Mn |
| Mar 31, 2026 | 389.89 Mn |
| Mar 31, 2026 | 389.89 Mn |
| Dec 31, 2025 | -4.94 Mn |
| Dec 31, 2025 | -4.94 Mn |
| Sep 30, 2025 | 71.53 Mn |
| Sep 30, 2025 | 71.53 Mn |
| Jun 30, 2025 | -152.31 Mn |
| Jun 30, 2025 | -152.31 Mn |
| Mar 31, 2025 | -123.23 Mn |
| Mar 31, 2025 | -123.23 Mn |
| Dec 31, 2024 | -40.44 Mn |
| Dec 31, 2024 | -40.44 Mn |
| Sep 30, 2024 | 176.16 Mn |
| Sep 30, 2024 | 176.16 Mn |
| Jun 30, 2024 | 146.75 Mn |
| Jun 30, 2024 | 146.75 Mn |
| Mar 31, 2024 | -19.74 Mn |
| Mar 31, 2024 | -19.74 Mn |